Delaugerre 2001.
| Methods | N=20 Non randomized Fup=unclear | |
| Participants | Eligibility:‐ Treatment failure VL>10,000 copies/ml for 36 months, CDC stage C 80% patients; Median ART 73months(29‐118) Median CD4 200 cells/mm3; Baseline median VL 160, 000 cop/ml | |
| Interventions | 8 wks TI (4‐24 wks) | |
| Outcomes | STI arm: Viral reversion: 55% participants | |
| Notes | ||
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Allocation concealment? | Unclear risk | D ‐ Not used |